Registro de fuente primaria
Grado decisivoAprobación de la FDA
Viatris: la FDA aprueba Gwyn Lo (parche de noretgestromina/etinilestradiol)
La FDA aprobó Gwyn Lo, un nuevo parche anticonceptivo hormonal combinado de dosis baja. Se espera que el producto esté disponible comercialmente a finales de este año, añadiendo un nuevo producto de marca al portafolio de Viatris.
Datos clave
- Presentado
- 6 ago 2026, 11:56
- Evento
- Aprobación de la FDA
- Dirección
- Positivo
- Empresa
VTRSViatris- Fuente
- SEC 8-K
- Confianza
- Con fuente
Extracto de la fuente
EX-99.1 2 exhibit991-2q26earningsrel.htm EX-99.1 Document Viatris Reports Second-Quarter 2026 Financial Results • Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million • Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 • Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 • Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn Lo TM • Announces Sale of Global Rights to Tyrvaya ® • Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x • Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH – August 6, 2026 – Viatris I